Pharma consolidates its grip on post-antibody landscape
Article Abstract:
The pharma industries are switching rapidly to the use and development of fully human antibodies and their fragments as these offer numerous advantages in terms of delivery routes and manufacturing and are highly stable molecules with low molecular weight. The antibody development strategies and achievements of a number of famous pharma companies are discussed in the article.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Lack of data mires Aranesp in controversy
Article Abstract:
The U.S. Food and Drug Administration's (FDA's) warning against Amgen's Aranesp (darbepoetin alfa) has affected the sales of this drug. Amgen's lobbying in Washington might be very affective as it does not have solid data on safe hemoglobin levels.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Cord blood cell therapy trial suspended. Pharma consolidates its grip on post-antibody landscape. It came from beneath the sea
- Abstracts: Polyclonal antibodies step out of the shadows. Supreme Court boosts licensees in biotech patent battles. GlaxoSmithKline cancer drug threatens Herceptin market
- Abstracts: Asset sales, investment opportunities, and the use of proceeds. Optimal asset location and allocation with taxable and tax-deferred investing
- Abstracts: The emancipatory potential of online reporting: the case of counter accounting. Mediating between colonizer and colonized in the American empire: accounting for government moneys in the Philippines
- Abstracts: The effect of camera viewing angle on posture assessment repeatability and cumulative spinal loading. The effects of lumbar massage on muscle fatigue, muscle oxygenation, low back discomfort, and driver performance during prolonged driving